Recent Updates
Recently added Catalysts
ALVO Positive Sentiment

Alvotech to present at upcoming investor conferences in September

Key Takeaway: Alvotech will present at two major investor conferences in September 2026. Robert Wessman and Dr. Balaji V. Prasad will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference and host investor meetings at Deutsche Bank's Healthcare Summit. A live webcast will be available for public access.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alvotech is actively engaging with investors through conferences.
  • The company has a strong portfolio of approved biosimilars.
  • Live webcasts increase transparency and accessibility for investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+128%
120-day peak, hindsight
Typical move
13.8%
average across 7 past catalysts
Lead asset
Stelara
Phase 3 · Psoriasis

Full Press Release Details

REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Founder and Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will participate in the upcoming investor conferences in September as follows:
• Morgan Stanley 24 th Annual Global Healthcare Conference in New York – Fireside chat on Tuesday, September 15, 2026 at 12:20 pm ET (16:20 GMT)
• Deutsche Bank's 2026 Healthcare Summit in New York – Hosting investor meetings on Thursday, September 17, 2026.
A live webcast of the fireside chat will be available to the general public and can be accessed in the Investors Section of Alvotech's website under Events and Presentations. After the event, a recording will be available for replay for 90 days.

Media Benedikt Stefansson Sarah MacLeod alvotech.media@alvotech.com

Investors Dr. Balaji V Prasad Benedikt Stefansson Mikaela Vilchez alvotech.ir@alvotech.com

About Alvotech

Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.

Frequently Asked Questions

Who will represent Alvotech at the conferences?

Robert Wessman and Dr. Balaji V. Prasad will represent Alvotech.

When is the Morgan Stanley conference?

The Morgan Stanley conference is on September 15, 2026.

How can I access the live webcast?

The live webcast can be accessed on Alvotech's website under Events and Presentations.

What is Alvotech's focus?

Alvotech specializes in the development and manufacture of biosimilar medicines.

Last updated: Aug 27, 2026